New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions

References

• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–6249s.
   PubMed Web of Science ®Google Scholar
• Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat. 2008;111:303–311.
   PubMed Web of Science ®Google Scholar
• Hess T, Egerer G, Kasper B, et al. Atypical manifestations of multiple myeloma: radiological appearance. Eur J Radiol. 2006;58:280–285.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5:667–676.
   PubMed Web of Science ®Google Scholar
• Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;9(Suppl 1):S7.
   PubMed Web of Science ®Google Scholar
• Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9:eaal4922.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Fromm A, Ahmed KA, et al. Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD -L1 negative metastatic squamous cell carcinoma of the lung. J Thorac Oncol. 2017;12:135–136.
   PubMedGoogle Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma. JAMA Oncol. 2017;3:e172411.
   PubMed Web of Science ®Google Scholar
• Burugu S, Dancsok AR, Nielsen TO, et al. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018;52(Pt 2):39–52.
   PubMed Web of Science ®Google Scholar
• Lee J, Byun H, Madhurakkat Perikamana SK, et al. Current advances in immunomodulatory biomaterials for bone regeneration. Adv Healthc Mater. 2018:e1801106. doi:10.1002/adhm.201801106. [Epub ahead of print].
   Google Scholar
• Ralston SH, Schett G. Osteoimmunology. Calcif Tissue Int. 2018;102:501–502.
   PubMed Web of Science ®Google Scholar
• Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5055.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170:427–435.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol. 2012;8:684–689.
   PubMed Web of Science ®Google Scholar
• Hon H, Rucker EB, Hennighausen L, et al. Bcl-xL is critical for dendritic cell survival in vivo. J Immunol. 2004;173:4425–4432.
   PubMed Web of Science ®Google Scholar
• Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol. 2001;166:1482–1491.
   PubMed Web of Science ®Google Scholar
• Milone F, Pivonello C, Cariati F, et al. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumour progression in patients with NET harboring bone metastases. Biomarkers. 2013;18:121–125.
   PubMed Web of Science ®Google Scholar
• Trouvin AP, Goeb V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging. 2010;5:345–354.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412–2424.
   PubMed Web of Science ®Google Scholar
• Baud’huin M, Duplomb L, Ruiz Velasco C, et al. Key roles of the OPG–RANK–RANKL system in bone oncology. Expert Rev Anticancer Ther. 2007;7:221–232.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–1664.
   PubMed Web of Science ®Google Scholar
• Merz M, Komljenovic D, Semmler W, et al. Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases. Invest Radiol. 2012;47:422–429.
   PubMed Web of Science ®Google Scholar
• Vetter M, Landin J, Szczerba BM, et al. Denosumab treatment is associated with the absence of circulating tumour cells in patients with breast cancer. Breast Cancer Res. 2018;20:141.
   PubMed Web of Science ®Google Scholar
• van der Heijden L, Dijkstra PDS, Blay JY, et al. Giant cell tumour of bone in the denosumab era. Eur J Cancer. 2017;77:75–83.
   PubMed Web of Science ®Google Scholar
• Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008;283:4283–4294.
   PubMed Web of Science ®Google Scholar
• Roudier MP, Morrissey C, True LD, et al. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008;180:1154–1160.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kusnadi A, Lee EJ, et al. Tumour-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol. 2012;278:76–83.
   PubMed Web of Science ®Google Scholar
• Raimondi G, Shufesky WJ, Tokita D, et al. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol. 2006;176:2808–2816.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumour-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human. Clin Cancer Res. 2013;19:1021–1034.
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190–198.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005;104:2084–2091.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Kim KM, Bae JS, et al. Tumour infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol. 2013;6:282–289.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634–642.
   PubMed Web of Science ®Google Scholar
• Hwang S, Panicek DM. The evolution of musculoskeletal tumour imaging. Radiol Clin North Am. 2009;47:435–453.
   PubMed Web of Science ®Google Scholar
• Miwa S, Taki J, Yamamoto N, et al. A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma. J Surg Oncol. 2012;106:273–279.
   PubMed Web of Science ®Google Scholar
• Noebauer-Huhmann IM, Weber MA, Lalam RK, et al. Soft tissue tumours in adults: ESSR-approved guidelines for diagnostic imaging. Semin Musculoskelet Radiol. 2015;19:475–482.
   PubMed Web of Science ®Google Scholar
• Bauerle T, Bartling S, Berger M, et al. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol. 2010;73:280–287.
   PubMed Web of Science ®Google Scholar
• Krasnow AZ, Hellman RS, Timins ME, et al. Diagnostic bone scanning in oncology. Semin Nucl Med. 1997;27:107–141.
   PubMed Web of Science ®Google Scholar
• Bauerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol. 2009;19:2495–2507.
   PubMed Web of Science ®Google Scholar
• Mulkens TH, Bellinck P, Baeyaert M, et al. Use of an automatic exposure control mechanism for dose optimization in multi-detector row CT examinations: clinical evaluation. Radiology. 2005;237:213–223.
   PubMed Web of Science ®Google Scholar
• Tombal B, Rezazadeh A, Therasse P, et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumour response on prostate cancer bone metastases. Prostate. 2005;65:178–187.
   PubMed Web of Science ®Google Scholar
• Vogel WV, Nestle U, Valli MC. PET/MRI in breast cancer. Clin Transl Imaging. 2017;5:71–78.
   Web of Science ®Google Scholar
• Pace L, Nicolai E, Luongo A, et al. Comparison of whole‐body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F‐deoxyglucose uptake in lesions and in normal organ tissues. Eur J Radiol. 2014;83:289–296.
   PubMed Web of Science ®Google Scholar
• Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–3379.
   PubMed Web of Science ®Google Scholar
• Hilner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the national oncologic PET registry. J Clin Oncol. 2008;26:2155–2161.
   PubMed Web of Science ®Google Scholar
• Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging. 2004;31:189–195.
   PubMed Web of Science ®Google Scholar
• Al-Ibraheem A, Buck AK, Benz MR, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer. 2013;119:1227–1234.
   PubMed Web of Science ®Google Scholar
• Fuglø HM, Jørgensen SM, Loft A, et al. The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging. 2012;39:1416–1424.
   PubMed Web of Science ®Google Scholar
• Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumours. Eur J Nucl Med Mol Imaging. 2009;36:23–36.
   PubMed Web of Science ®Google Scholar
• Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36:113–120.
   Web of Science ®Google Scholar
• Schäfer JF, Gatidis S, Schmidt H, et al. Simultaneous whole‐body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology. 2014;273:220–231.
   PubMed Web of Science ®Google Scholar
• Schmidkonz C, Ellmann S, Ritt P, et al. Hybrid imaging (PET-computed tomography/PET-MR imaging) of bone metastases. PET Clin. 2019;14:121–133.
   PubMed Web of Science ®Google Scholar
• Behzadi AH, Raza SI, Carrino JA, et al. Applications of PET/CT and PET/MR imaging in primary bone malignancies. PET Clin. 2018;13:623–634.
   PubMed Web of Science ®Google Scholar
• Catalano OA, Masch WR, Catana C, et al. An overview of PET/MR, focused on clinical applications. Abdom Radiol. 2017;42:631–644.
   PubMed Web of Science ®Google Scholar
• Shah SN, Huang SS. Hybrid PET/MR imaging: physics and technical considerations. Abdom Imaging. 2015;40:1358–1365.
   PubMedGoogle Scholar
• Gary JR, Gnanasegaran G, Chua S. Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumours. Semin Nucl Med. 2010;40:52–61.
   PubMed Web of Science ®Google Scholar
• Coleman R, Body JJ, Aapro M. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25:124–137.
   Web of Science ®Google Scholar
• Ghosh P. The role of SPECT/CT in skeletal malignancies. Semin Musculoskelet Radiol. 2014;18:175–193.
   PubMed Web of Science ®Google Scholar
• Quarles van Ufford HM, van Tinteren H, Stroobants SG, et al. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumours to systemic cytotoxic neoadjuvant treatment: a meta-analysis. J Nucl Med. 2010;51:1507–1516.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumours. J Clin Oncol. 2005;23:8828–8834.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Rajendran JG, Eu C, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer. 2002;94:3277–3284.
   PubMed Web of Science ®Google Scholar
• Aoki J, Endo K, Watanabe H, et al. FDG-PET for evaluating musculoskeletal tumours: A review. J Orthop Sci. 2003;8:435–441.
   PubMedGoogle Scholar
• Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540–548.
   PubMed Web of Science ®Google Scholar
• Incoronato M, Grimaldi AM, Cavaliere C, et al. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study. Eur J Nucl Med Mol Imaging. 2018;45:1680–1693.
   PubMed Web of Science ®Google Scholar
• Ohba Y, Nomori H, Mori T, et al. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with udeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg. 2009;138:439–445.
   PubMed Web of Science ®Google Scholar
• Choi SY, Chang YW, Park HJ, et al. Correlation of diffusion-weighted imaging apparent diffusion coefficient with prognostic factors of breast cancer. Br J Radiol. 2012;85:474–479.
   PubMed Web of Science ®Google Scholar
• Bajpai J, Gamnagatti S, Kumar R, et al. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol. 2011;41:441–450.
   PubMed Web of Science ®Google Scholar
• Uhl M, Saueressig U, van Buiren M, et al. Preliminary results of in vivo assessment of tumour necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol. 2006;41:618–623.
   PubMed Web of Science ®Google Scholar
• Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumours by diffusion- weighted image: initial results. Eur Radiol. 2006;16:2637–2643.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Zanella L, Cacciatore F, et al. YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma. BMC Cancer. 2011;11:472–476.
   PubMed Web of Science ®Google Scholar
• Yu L, Liu S, Guo W, et al. Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression. Oncol Rep. 2012;28:2170–2176.
   PubMed Web of Science ®Google Scholar
• Xu J, Wu S, Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 2010;28:1621–1625.
   PubMed Web of Science ®Google Scholar
• Wang YH, Han XD, Qiu Y, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumour metastasis and prognosis in patients with osteosarcoma. J Surg Oncol. 2012;105:235–243.
   PubMed Web of Science ®Google Scholar
• Singer FR, David RE. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med. 2008;75:739–750.
   PubMed Web of Science ®Google Scholar
• Babkina IV, Osipov DA, Solovyov YN, et al. Endostatin, placental growth factor, and fibroblast growth factors-1 and −2 in the sera of patients with primary osteosarcomas. Bull Exp Biol Med. 2009;148:246–249.
   PubMed Web of Science ®Google Scholar
• Baumhoer D, Elsner M, Smida J, et al. CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients. Oncotarget. 2011;2:970–975.
   PubMedGoogle Scholar
• Bramer J, Abudu A, Tillman R, et al. Pre-and post-chemotherapy alkaline phosphatase levelsas prognostic indicators in adults with localized osteosarcoma. Eur J Cancer. 2005;41:2846–2852.
   PubMed Web of Science ®Google Scholar
• Behjati S, Tarpey PS, Haase K, et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun. 2017;8:15936.
   PubMed Web of Science ®Google Scholar
• Ren Z, Liang S, Yang J, et al. Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma. Tumour Biol. 2016;37:5089–5096.
   PubMedGoogle Scholar
• Lu Y, Guan GF, Chen J, et al. Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival. Oncol Lett. 2015;10:2123–2129.
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Gershtein ES, Solov’ev YN, et al. Receptor activator of nuclear transcription factor NF-κB (RANK), its ligand RANKL, and natural inhibitor of RANKL osteoprotegerin (OPG) in the blood serum of patients with primary bone tumors. Bull Exp Biol Med. 2017;163:478–481.
   PubMed Web of Science ®Google Scholar
• de Andrea CE, Reijnders CM, Kroon HM, et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene. 2012;31:1095–1104.
   PubMed Web of Science ®Google Scholar
• Lechler P, Renkawitz T, Campean V, et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer. 2011;11:120.
   PubMed Web of Science ®Google Scholar
• de Jong Y, van Oosterwijk JG, Kruisselbrink AB, et al. Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis. 2016;5:e222.
   PubMed Web of Science ®Google Scholar
• Liu JQ, Zhang QH, Wang ZL. Clinicopathological significance of p16, cyclin D1, Rb and MIB-1 levels in skull base chordoma and chondrosarcoma. World J Otorhinolaryngol Head Neck Surg. 2015;1:50–56.
   PubMedGoogle Scholar
• Guan H, Zhou Z, Cao Y, et al. VEGF165 promotes the osteolytic bone destruction of Ewing’s sarcoma tumors by upregulating RANKL. Oncol Res. 2009;18:117–125.
   PubMed Web of Science ®Google Scholar
• Sexton CW, White WL. Primary cutaneous Ewing’s family sarcoma. Report of a case with immunostaining for glycoprotein p30/32 mic2. Am J Dermatopathol. 1996;18:601–605.
   PubMed Web of Science ®Google Scholar
• Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat Rev Dis Primers. 2018;4:5.
   PubMed Web of Science ®Google Scholar
• Douglas D, Hsu J, Hung L, et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 2008;68:6507–6515.
   PubMed Web of Science ®Google Scholar
• Kaseta MK, Gomatos IP, Khaldi L, et al. Prognostic value of bax, cytochrome C, and caspase-8 protein expression in primary osteosarcoma. Hybridoma. 2007;26:355–362.
   PubMedGoogle Scholar
• Won KY, Park HR, Park YK. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori. 2009;95:311–316.
   PubMed Web of Science ®Google Scholar
• Luo X, Chen J, Song WX, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbour differentiation defects. Lab Invest. 2008;88:1264–1277.
   PubMed Web of Science ®Google Scholar
• Sandhu R, Lal H, Kundu ZS, et al. Serum fluoride and sialic acid levels in osteosarcoma. Biol Trace Elem Res. 2011;144:1–5.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Ishikawa T, Iwai S, et al. Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma. Mol Cancer Res. 2012;10:454–468.
   PubMed Web of Science ®Google Scholar
• Lu BJ, Wang YQ, Wei XJ, et al. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep. 2012;5:1033–1036.
   PubMed Web of Science ®Google Scholar
• Jin S, Shen JN, Peng JQ, et al. Decreased expression of serum gelsolin in patients with osteosarcoma. Chin Med J. 2012;125:262–269.
   PubMed Web of Science ®Google Scholar
• Zambo I, Hermanova M, Adamkova Krakorova D, et al. Nestin expression in high-grade osteosarcomas and its clinical significance. Oncol Rep. 2012;27:1592–1598.
   PubMed Web of Science ®Google Scholar
• Tan P, Zou C, Yong B, et al. Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Comm. 2012;419:801–808.
   PubMed Web of Science ®Google Scholar
• Li Y, Flores R, Yu A, et al. Elevated expression of CXC chemochines in pediatric osteosarcoma patients. Cancer. 2011;117:207–217.
   PubMed Web of Science ®Google Scholar
• Sharili AS, Allen S, Smith K, et al. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy. Tumor Biol. 2011;32:515–526.
   PubMedGoogle Scholar
• Funovics PT, Edelhauser G, Funovics MA, et al. Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop. 2011;35:1529–1536.
   PubMed Web of Science ®Google Scholar
• Perbal B, Lazar N, Zambelli D, et al. Prognostic value of CCN3 in osteosarcoma. Hum Pathol. 2009;40:1479–1486.
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo C, Wang H, et al. CEACAM6 is associated with osteosarcoma metastasis and facilitates epithelial–mesenchymal transition in osteosarcoma cells. Onco Targets Ther. 2018;1:3159–3166.
   Google Scholar
• Wei H, Zhao MQ, Dong W, et al. Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance. J Int Med Res. 2008;36:1008–1014.
   PubMed Web of Science ®Google Scholar
• Levings PP, McGarry SV, Currie PV, et al. Expression of an exogenous human Oct- 4promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009;69:5648–5655.
   PubMed Web of Science ®Google Scholar
• Wang ZX, Yang JS, Pan X, et al. Functional and biological analysis of Bcl-xL expression in human osteosarcoma. Bone. 2010;47:445–454.
   PubMed Web of Science ®Google Scholar
• Lockwood WW, Stack D, Morris T, et al. Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn. 2011;13:289–296.
   PubMed Web of Science ®Google Scholar
• Folio C, Zalacain M, Zandueta C, et al. Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival. Cancer Biomark. 2011;10:35–41.
   PubMed Web of Science ®Google Scholar
• Chen P, Wang SJ, Wang HB, et al. The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. J Mol Histol. 2012;43:63–70.
   PubMed Web of Science ®Google Scholar
• Hallor KH, Staaf J, Bovée JV, et al. Genomic profiling of hondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res. 2009;15:2685–2694.
   PubMed Web of Science ®Google Scholar
• Szuhai K, Cleton-Jansen AM, Hongedoorn PCW, et al. Molecular pathology and its diagnostic use in bone tumors. Can Genet. 2012;205:193–204.
   PubMed Web of Science ®Google Scholar
• Hogendoorn PC, Athanasou N, Bielack S, et al. Esmo/Eurobonet Working Group, Athanasou N, et al. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):204–213.
   PubMedGoogle Scholar
• Rozeman LB, Hameetman L, Cleton-Jansen AM, et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol. 2005;205:4.476–482.
   PubMed Web of Science ®Google Scholar
• Liang X, Wang D, Wang Y, et al. Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol. 2012;7:84.
   PubMed Web of Science ®Google Scholar
• Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–343.
   PubMed Web of Science ®Google Scholar
• Rozeman LB, Inge H, De Bruijn B, et al. Dedifferentiated peripheral chondrosarcomas: regulation of EXTdownstream molecules and differentiation-related genes. Mod Pathol. 2009;22:1489–1498.
   PubMed Web of Science ®Google Scholar
• Tsai CH, Yang DY, Lin CY, et al. Sphingosine-1-phosphate suppresses chondrosarcoma metastasis by upregulation of tissue inhibitor of metalloproteinase 3 through suppressing miR-101 expression. Mol Oncol. 2017;11:1380–1398.
   PubMed Web of Science ®Google Scholar
• Aviel-Ronen S, Zadok O, Vituri A, et al. α-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas. Sci Rep. 2016;6:21277.
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Hur K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35:2731–2739.
   PubMed Web of Science ®Google Scholar
• Feng H, Wang J, Xu J, et al. The expression of SIRT1 regulates the metastatic plasticity of chondrosarcoma cells by inducing epithelial-mesenchymal transition. Sci Rep. 2017;7:41203.
   PubMed Web of Science ®Google Scholar
• Yang WH, Chen JC, Hsu KH, et al. Leptin increases VEGF expression and enhances angiogenesis in human chondrosarcoma cells. Biochim Biophys Acta. 2014;1840:3483–3493.
   PubMed Web of Science ®Google Scholar
• Zenmyo M, Tanimoto A, Sakakima H, et al. Gadd45b expression in chondrosarcoma: a pilot study for diagnostic and biological implications in histological grading. Diagn Pathol. 2010;5:69.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li J, Song Y, et al. MiR-129–5p inhibits proliferation and invasion of chondrosarcoma cells by regulating SOX4/Wnt/β-catenin signaling pathway. Cell Physiol Biochem. 2017;42:242–253.
   PubMed Web of Science ®Google Scholar
• Liu GT, Huang YL, Tzeng HE, et al. CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. Cancer Lett. 2015;357:476–487.
   PubMed Web of Science ®Google Scholar
• Sheng W, Zhang ZC, Shi DY, et al. Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation. Chem Biol Interact. 2018;296:1–8.
   PubMed Web of Science ®Google Scholar
• Jamil N, Howie S, Salter DM. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol. 2010;91:387–393.
   PubMed Web of Science ®Google Scholar
• Meijer D, Gelderblom H, Karperien M, et al. Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clin Sarcoma Res. 2011;1:5.
   PubMedGoogle Scholar
• Cintra F, Etchebehere M, Gonçalves JCB, et al. Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors - clinical and histological correlation. Clinics. 2011;66:1591–1596.
   PubMed Web of Science ®Google Scholar
• Nakagawa SA, Lopes A, Lopes de Carvalho A, et al. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am. 2010;92:1738–1746.
   PubMedGoogle Scholar
• Ariizumi T, Ogose A, Kawashima H, et al. Expression of podoplanin in human bone and bone tumors: new marker of osteogenic and chondrogenic bone tumors. Pathol Int. 2010;60:193–202.
   PubMed Web of Science ®Google Scholar
• Papachristou DJ, Gkretsia V, Raoa UNM, et al. Expression of integrinlinked kinase and its binding partners inchondrosarcoma: association with prognostic significance. Eur J Cancer. 2008;44:2518–2525.
   PubMed Web of Science ®Google Scholar
• Yang SN, Chen HT, Tsou HK, et al. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. Carcinogenesis. 2009;30:566–574.
   PubMed Web of Science ®Google Scholar
• Lee HP, Lin CY, Shih JS, et al. Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway. Oncotarget. 2015;6:5479.
   Google Scholar
• Lai X, Chen S. Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma. Proteomics. 2015;15:2358–2368.
   PubMed Web of Science ®Google Scholar
• Karamchandani JR, Nielsen TO, van de Rijn M, et al. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20:445–450.
   PubMedGoogle Scholar
• Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle. 2008;15:250–256.
   Google Scholar
• Bachmaier R, Aryee DN, Jug G, et al. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing’s sarcoma. Oncogene. 2009;28:1280–1284.
   PubMed Web of Science ®Google Scholar
• Aryee DN, Niedan S, Kauer M, et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of ewing’s sarcoma cells in vitro. Cancer Res. 2010;70:4015–4023.
   PubMed Web of Science ®Google Scholar
• Cooper A, van Doorninck J, Ji L, et al. Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the children’s oncology group. Clin Cancer Res. 2011;17:56–66.
   PubMed Web of Science ®Google Scholar
• Bennani-Baiti IM, Cooper A, Lawlor ER, et al. Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing’s. Clin Cancer Res. 2010;16:3769–3778.
   PubMed Web of Science ®Google Scholar
• Mackintosh C, Ordóñez JL, García-Domínguez DJ, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2012;31:1287–1298.
   PubMed Web of Science ®Google Scholar
• Huang G, Zhou Z, Wang H, et al. CAPER-a alternative splicing regulates the expression of vascular endothelial growth factor in Ewing sarcoma cells. Cancer. 2012;118:2106–2116.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2006;15:32–38.
   PubMed Web of Science ®Google Scholar
• Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002;20:850–856.
   PubMed Web of Science ®Google Scholar
• Goranova-Marinova V, Goranov S, Pavlov P, et al. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clin Correlations Haematol. 2007;97:1000–1001.
   Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254–1266.
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25:4431–4437.
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M, et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res. 2010;25:463–471.
   PubMed Web of Science ®Google Scholar
• Ribi S, Baumhoer D, Lee K, et al. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. Oncotarget. 2015;6:7727–7740.
   PubMedGoogle Scholar
• Martin JW, Chilton-MacNeill S, Koti M, et al. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One. 2014;9:e95843.
   PubMed Web of Science ®Google Scholar
• Zuffa E, Mancini M, Brusa G, et al. P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2. Int J Radiat Biol. 2008;84:591–601.
   PubMed Web of Science ®Google Scholar
• Baldini N, Scotlandi K, Barbanti-Br`odano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333(21):1380–1385.
   PubMed Web of Science ®Google Scholar
• Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561–2567.
   PubMed Web of Science ®Google Scholar
• Dass CR, Nadesapillai AP, Robin D, et al. Downregulation of uPAR conWrms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis. 2005;22:643–652.
   PubMed Web of Science ®Google Scholar
• Osaka E, Suzuki T, Osaka S, et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem. 2006;39:95–100.
   PubMed Web of Science ®Google Scholar
• Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2005;23:1483–1490.
   PubMed Web of Science ®Google Scholar
• Overholtzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA. 2003;100:11547–11552.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Rossiello R, Schiano C, et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res. 2008;68:1797–1808.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Mancini FP, Schiano C, et al. Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis. J Cell Physiol. 2013;228:846–852.
   PubMed Web of Science ®Google Scholar
• Abbondanza C, de Nigris F, De Rosa C, et al. Silencing of YY1 downregulates RIZ1 promoter in human osteosarcoma. Oncol Res. 2008;17:33–41.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Botti C, de Chiara A, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006;42:2420–2424.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res. 2012;192:197–223.
   PubMedGoogle Scholar
• de Nigris F, Schiano C, Infante T, et al. CXCR4 inhibitors: tumour vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012;7:251–264.
   PubMed Web of Science ®Google Scholar
• Xiang J, Hurchla MA, Fontana F, et al. CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol Cancer Ther. 2015;14:2473–2485.
   PubMed Web of Science ®Google Scholar
• Bellanger A, Donini CF, Vendrell JA, et al. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone. J Pathol. 2017;242:73–89.
   PubMed Web of Science ®Google Scholar
• Savci-Heijink CD, Halfwerk H, Hooijer GKJ, et al. Retrospective analysis of metastatic behavior of breast cancer subtypes. BC Res Treat. 2015;150:547–557.
   PubMed Web of Science ®Google Scholar
• Westbrook JA, Cairns DA, Peng J, et al. CAPG and GIPC1: BC biomarkers for bone metastasis development and treatment. J Natl Cancer Inst. 2016;108:djv360.
   Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;44:682–689.
   Google Scholar
• Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Bio. 2008;10:201–210.
   Web of Science ®Google Scholar
• Hassan MQ, Maeda Y, Taipaleenmaki H, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. Biol Chem. 2012;287:42084–42092.
   Web of Science ®Google Scholar
• Liu J, Li D, Dang L, et al. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Nature. 2017;7:40487.
   Google Scholar
• Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–152.
   PubMed Web of Science ®Google Scholar
• Dolloff NG, Shulby SS, Nelson AV, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor. Oncogene. 2005;24:6848–6854.
   PubMed Web of Science ®Google Scholar
• Russell MR, Jamieson WL, Dolloff NG, et al. The α-receptor for plateletderived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene. 2009;28:412–421.
   PubMed Web of Science ®Google Scholar
• Liu Q, Russell MR, Shahriari K, et al. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Res. 2013;73:3297–3305.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhong T. The association of CXCR4 expression with clinic-pathological significance and potential drug target in prostate cancer: a meta-analysis and literature review. Drug Des Dev Ther. 2015;9:5115–5122.
   PubMed Web of Science ®Google Scholar
• Gururajan M, Josson S, Chu GC, et al. miR-154 and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res. 2014;20:6559–6569.
   PubMed Web of Science ®Google Scholar
• Peng X, Guo W, Liu T, et al. Identification of miRs-143 and −145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011;6:e20341.
   PubMed Web of Science ®Google Scholar
• Saini S, Majid S, Yamamura S, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17:5287–5298.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang M, Zhu J, et al. Screening of gene mutations associated with bone metastasis in non small cell lung cancer. J Can Res Ther. 2016;12:186–190.
   Web of Science ®Google Scholar
• Seetharamu N, Budman DR, Sullivan KM. Immune checkpoint inhibitors in lung cancer: past, present and future. Future Oncol. 2016;12:1151–1163.
   PubMed Web of Science ®Google Scholar
• Papotti M, Kalebic T, Volante M, et al. Bone sialoprotein is predictive of bone metastases in resectable non small cell lung cancer: a retrospective case-control study. J Clin Oncol. 2006;24:4818–4824.
   PubMed Web of Science ®Google Scholar
• Hiraki A, Ueoka H, Bessho A, et al. Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer. 2002;95:1706–1713.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Ely B, Quinn DI, et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014;106:1–9.
   Google Scholar
• Kong QQ, Sun TW, Dou QY, et al. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers. 2007;22:214–220.
   PubMed Web of Science ®Google Scholar
• Kuo PL, Liao SH, Hung JY, et al. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta. 2013;1830:3756–3766.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen ZW, Yang XH, et al. Establishment of a biomarker model for predicting bone metastasis in resected stage III non small cell lung cancer. J Exp Clin Cancer Res. 2012;31:1–6.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Banerji S, Lawrance W, et al. Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nat Immunol. 2017;18:762–770.
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Birner P, Studer P, et al. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res. 2001;21:2351–2355.
   PubMed Web of Science ®Google Scholar
• Koltowska K, Banerji S, Lawrance W, et al. Getting out and about: the emergence and morphogenesis of the vertebrate lymphatic vasculature. Development. 2013;140:1857–1870.
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2:1125–1131.
   PubMed Web of Science ®Google Scholar
• Diamond P, Labrinidis A, Martin SK, et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res. 2009;24:1150–1161.
   PubMed Web of Science ®Google Scholar
• Zeng H, Wei W, Xu X. Chemokine (C-X-C motif) receptor 4 RNA interference inhibits bone metastasis in breast cancer. Oncol Lett. 2014;8:77–81.
   PubMed Web of Science ®Google Scholar
• Hardaway AL, Herroon MK, Rajagurubandara E, et al. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metastasis. 2015;32:353–368.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127.
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009;152:15–32.
   PubMedGoogle Scholar
• Houzé P, Bellik B, Extra JM, et al. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer. Clin Chim Acta. 1999;281:77–88.
   PubMed Web of Science ®Google Scholar
• Burak Z, Ersoy O, Moretti JL, et al. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med. 2001;28:1341–1350.
   PubMedGoogle Scholar
• Parghane RV, Singh B, Sharma A, et al. Role of 99mTc-methylene diphosphonate SPECT/CT in the detection of sacroiliitis in patients with spondyloarthropathy: comparison with clinical markers and MRI. J Nucl Med Technol. 2017;45:280–284.
   PubMed Web of Science ®Google Scholar
• Salaun PY, Gastinne T, Bodet-Milin C, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging. 2009;36:1813–1821.
   PubMed Web of Science ®Google Scholar
• Hoshi M, Takada J, Oebisu N, et al. Overexpression of hexokinase-2 in giant cell tumour of bone is associated with false positive in bone tumour on FDG-PET/CT. Arch Orthop Trauma Surg. 2012;132:1561–1568.
   PubMed Web of Science ®Google Scholar
• Lee JW, Choi JS, Lyu J, et al. Prognostic significance of 18F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer. Lung Cancer. 2018;118:41–47.
   PubMed Web of Science ®Google Scholar
• Lee JW, Jeon S, Mun ST, et al. Prognostic value of fluorine-18 fluorodeoxyglucose uptake of bone marrow on positron emission tomography/computed tomography for prediction of disease progression in cervical cancer. Int J Gynecol Cancer. 2017;27:776–783.
   PubMed Web of Science ®Google Scholar
• Perez-Lopez R, Nava Rodrigues D, Figueiredo I, et al. Multiparametric magnetic resonance imaging of prostate cancer bone disease: correlation with bone biopsy histological and molecular features. Invest Radiol. 2018;53:96–102.
   PubMed Web of Science ®Google Scholar
• Estorch M, Carrio I. Future challenges of multimodality imaging. Recent Results Cancer Res. 2013;187:403–415.
   PubMedGoogle Scholar